Abstract：Objective To observe the survival and side effects of stereotactic body radiotherapy (SBRT) in large hepatocellular carcinoma (HCC) patients. Methods Twenty-eight large HCC patients undergoing SBRT in 302 Military Hospital from November 1,2011 to January 31,2014 were observed. The prescribed dose was 39-61Gy/3-9f. Among them,20 patients simultaneously received transcatheter arterial embolization. The overall survival (OS), progression-free survival (PFS) and local control (LC) rates were calculated by using Kaplan-Meier method. The influencing factors of OS were analyzed by Cox regression model. The influencing factors of radiation-induced liver disease (RILD) were identified by using Logistic regression analysis. Results The 1-,2-,3-and 5-year OS rates were 75%,57%,54% and 22%, respectively. The 1-,2-,3-and 5-year PFS rates were 59%,47%,36% and 18%, respectively. The 1-,2-,3-and 5-year LC rates were 92%,86%,86% and 86%, respectively. Four patients suffered from RILD and none died from RILD. Child-Pugh classification was the influencing factor of OS and RILD. Conclusion It is preliminarily believed that SBRT is an alternative and safe treatment for patients with large HCC.
Sun Jing,Zhang Aimin,Li Wengang et al. Observation of clinical efficacy of stereotactic body radiotherapy in 28 cases of large hepatocellular carcinoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(10): 749-752.
[1] Kimura K,Nakamura T,Ono T,et al. Clinical results of proton beam therapy for hepatocellular carcinoma over5 cm[J]. Hepatol Res,2017,47(13). DOI:10.1111/hepr.12874. [2] Bruix Jordi,Sherman Morris,American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma:an update[J]. Hepatology,2011,53(3):1020-1022. DOI:10.1002/hep.24199. [3] Wan YL,Lai ECH. Salvage surgery following downstaging of unresectable hepatocellular carcinoma-A strategy to increase resectability[J]. Ann Surg Oncol,2007,14(12):3301-3309. DOI:10.1245/s10434-007-9549-7. [4] Lencioni R,Crocetti L. Local-regional treatment of hepatocellular carcinoma[J]. Radiology,2012,262(1):43-58. DOI:10.1148/radiol.11110144. [5] Benedict SH,Yenice KM,Followill D,et al. Stereotactic body radiation therapy:The report of AAPM Task Group 101[J]. Med Phys,2010,37(8):4078-4101. DOI:10.1118/1.3438081. [6] Cox JD,Stetz J,Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys,1995,31(5):1341-1346. DOI:10.1016/0360-3016(95)00060-C. [7] Pan-Charlie C,Kavanagh-Brian D,Dawson-Laura A,et al. Radiation-associated liver injury[J]. Int J Radiat Oncol Biol Phys,2010,76(3 Suppl):S94-100. DOI:10.1016/j.ijrobp.2009.06.092. [8] Venook AP,Stagg RJ,Lewis BJ,et al. Chemoembolization for hepatocellular carcinoma[J]. J Clin Oncol,1990,8(6):1108-1114. DOI:10.1200/JCO.1990.8.6.1108. [9] Keith S. Chemoembolization in the management of liver tumors[J]. Oncologist,2003,8(5):425-437. [10] Roche A,Girish B,de Baère T,et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors[J]. Eur Radiol,2003,13(1):136-140. DOI:10.1007/s00330-002-1558-0. [11] Zhou XD,Tang ZY,Yang BH,et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma[J]. Cancer,2001,91(8):1479-1486. [12] Zhao HC,Wu RL,Liu FB,et al. A retrospective analysis of long term outcomes in patients undergoing hepatic resection for large (>5 cm) hepatocellular carcinoma[J]. HPB,2016,18(11):943-949. DOI:10.1016/j.hpb.2016.08.005. [13] Xu Y,Shen Q,Wang N,et al. Percutaneous microwave ablation of 5-6 cmunresectable hepatocellular carcinoma:local efficacy and long-term outcomes[J]. Int J Hyperthermia,2016. DOI:10.1080/02656736.2016.1239842. [14] Blomgren H,Lax I,Nslund I,et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients[J]. Acta Oncol,1995,34(6):861-870. [15] Klein J,Dawson LA. Hepatocellular carcinoma radiation therapy:review of evidence and future opportunities[J]. Int J Radiat Oncol Biol Phys,2013,87(1):22-32. DOI:10.1016/j.ijrobp.2012.08.043. [16] Kang JK,Kim MS,Cho CK,et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization[J]. Cancer,2012,118(21):5424-5431. DOI:10.1002/cncr.27533. [17] O′Connor JK,Trotter J,Davis G,et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation[J]. Liver Transpl,2012,18(8):949-954. DOI:10.1002/lt.23439. [18] Huang WY,Jen YM,Lee MS,et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys,2012,84(2):355-61. DOI:10.1016/j.ijrobp.2011.11.058. [19] Su TS,Lu HZ,Cheng T,et al. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma>5 cm[J]. BMC Cancer,2016,16(1):834. DOI:10.1186/s12885-016-2894-9. [20] Kimura K,Nakamura T,Ono T,et al. Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm[J]. Hepatol Res,2017,47(13):1368-1374. DOI:10.1111/hepr.12874. [21] Liang SX,Zhu XD,Xu ZY,et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma:the risk factors and hepatic radiation tolerance[J]. Int J Radiat Oncol Biol Phys,2006,65(2):426-34. DOI:10.1016/j.ijrobp.2005.12.031. [22] Cheng JS,Chia H,Wu JK,et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease[J]. Int J Radiat Oncol Biol Phys,2004,60(5):1502-1509. DOI:10.1016/j.ijrobp.2004.05.048. [23] Jung JH,Yoon SM,Kim SY,et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma:clinical and dose-volumetric parameters[J]. Radiat Oncol,2013,8:249. DOI:10.1186/1748-717X-8-24.
2019, Vol. 28 
